Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting

Key Therapeutic Mechanisms of Clinical Activity for Autoimmune Diseases, including B cell Depletion, Tissue Infiltration and Immune Reconstitution Data, from Phase 1 Study of FT819 in Relapsed /...

Related Keywords

Maryland ,United States ,Baltimore ,San Diego ,California ,American ,Christina Tartaglia ,Nasdaq ,Stern Investor Relations Inc ,Exchange Commission ,American Society Of Gene ,Fate Therapeutics Inc ,Key Therapeutic Mechanisms ,Clinical Activity ,Autoimmune Diseases ,Tissue Infiltration ,Immune Reconstitution Data ,Refractoryb Cell Malignancies ,Enrollment Initiated ,Systemic Lupus ,American Society ,Cell Therapy ,Annual Meeting ,Cell Based Gene Therapy ,Genetically Modified Immune Cells ,Tuesday May ,Fate Therapeutic ,Fate Therapeutics ,Private Securities Litigation Reform Act ,Investor Relations ,Markets ,